Malnutrition and Inflammation in Dialysis Patients in Taiwan

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00173823
First received: September 13, 2005
Last updated: March 10, 2006
Last verified: August 2005
  Purpose

According to the reports of the United States Renal Data System (USRDS), there is a 25% annual mortality rate with nearly 50% of all reported maintenance hemodialysis (HD) patient deaths attributed to atherosclerosis-related complications. Although traditional risk factors of cardiovascular disease (CVD) are common in end-stage renal disease (ESRD) patients, they alone may be insufficient to account for their high prevalence of CVD. Recent evidence demonstrated high plasma homocysteine levels have been established as a risk factor of chronic inflammation and atherosclerosis in patients with ESRD.

Malnutrition and inflammation was associated with poor quality of life, morbidity and mortality. We, the researchers at National Taiwan University Hospital, hope to establish the best predictive profile of HD patient outcome. Thus, we establish several protocols to complete this work.


Condition
Hemodialysis
Hypercholesterolemia
Malnutrition
Inflammation
Kidney Failure, Chronic

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: Malnutrition and Inflammation in Taiwan: Prospective Outcome Evaluation Method (MIT-POEM) in Dialysis Patients

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 1500
Study Start Date: June 2004
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • On HD three times a week for more than 3 months (minimizing the confounding effects of residual renal function)

Exclusion Criteria:

  • Malignancy;
  • Obvious infections or inflammatory diseases;
  • Preexisting haematological disorders; and,
  • Clinically significant bleeding, transfusion, hospitalization, surgery, or renal transplantation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00173823

Locations
Taiwan
National Taiwan University Hospital and collegues Recruiting
Taipei, Taiwan
Contact: Chih-Kang Chiang, MD    +886-23123456 ext 3921    ckchiang@ha.mc.ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Chih-Kang Chiang, MD National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00173823     History of Changes
Other Study ID Numbers: 9461700840
Study First Received: September 13, 2005
Last Updated: March 10, 2006
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Hypercholesterolemia
Inflammation
Kidney Failure, Chronic
Renal Insufficiency
Malnutrition
Nutrition Disorders
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Pathologic Processes
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on August 28, 2014